Mindvision marks Lupin’s foray into Neuropsychiatry. Launched in 2007 Mindvision has been one of the fastest growing division of LUPIN.

Mindvision caters to specific therapeutic segments in CNS such as Stroke, Dementia, Depression, Anxiety and Pain.

Right from the inception Mindvision’s objective is to build brands. Over time MINDVISION has strategically build brands like STALOPAM PLUS (Escitalopram + Clonazepam) Ranked number 1, (Source : ORG Jan MAT 2011 ) and CITISTAR (Citicoline) ranked Number 3 (Source : ORG Jan MAT 2011 )

Mindvision has always been driven by valuable inititatives that it has taken since the time it was launched these include…

2011 – 2012 : Launch of revolutionary treatment for Stroke, Dementia and Traumatic Brain Injury with the launch og Cognistar – Cerebroprotein Hydrolysate. The product is available in 44 countries and LUPIN MINDVISION is the first CNS company to bring the product to India. The product has a large clinical backup with over 170 clinical trials in Stroke Dementia and Traumatic Brain Injury. The scientific papers on the product have been presented at various international Neurological Symposiums.

2010 – 2011 - Launch of Novel analgesics like Lupirtin (Flupirtine Maleate) and Transdol (Tapentadol) first time in India to cater to Pain segment.

2009 – 2010 – Launch of first time in India Dementia Product MEMPIL – Huperazine alpha – which works on Dementia in a multi modal way.

2008 – 2009: Exclusive scientific educational tie up with the European Neurological Society (ENS), which aids in conducting knowledge exchange programmes between faculty from ENS and Indian Experts in Neurology

Key Products: